Brief: Bicycle Therapeutics Says Announces Expedited Development Plan For Bt8009 In Metastatic Bladder Cancer
11/09/2023 12:28
Sept 11 (Reuters) - Bicycle Therapeutics PLC BCYC.O :
* BICYCLE THERAPEUTICS PLC - ANNOUNCES EXPEDITED DEVELOPMENT
PLAN
FOR BT8009 IN METASTATIC BLADDER CANCER
* BICYCLE THERAPEUTICS PLC - ALIGNMENT WITH U.S. FDA ON
DESIGN OF
PHASE 2/3 REGISTRATIONAL TRIAL, TO BE INITIATED IN 1Q 2024
* BICYCLE THERAPEUTICS PLC - DISCUSSIONS WITH FDA ABOUT
DESIGN OF
CONFIRMATORY TRIAL FOR PREVIOUSLY TREATED METASTATIC BLADDER
CANCER ARE ONGOING
Source text for Eikon: ID:nBw46Znzca
Further company coverage: BCYC.O
((Reuters.Brief@thomsonreuters.com;))
Recent news on Bicycle Therapeutics
See all newsBicycle Therapeutics PLC reports results for the quarter ended September 30 - Earnings Summary
UK's Bicycle Therapeutics Q3 loss narrows as expenses fall
Bicycle Therapeutics PLC expected to post a loss of 43 cents a share - Earnings Preview
UK's Bicycle Therapeutics Q2 net loss narrows on reduced clinical program expenses
Bicycle Therapeutics Q1 revenue drops after partnership terminations